Welcome to our dedicated page for Verastem news (Ticker: VSTM), a resource for investors and traders seeking the latest updates and insights on Verastem stock.
Verastem Oncology develops and commercializes oncology medicines for RAS/MAPK pathway-driven cancers. The company markets AVMAPKI FAKZYNJA CO-PACK in the U.S. for KRAS-mutated recurrent low-grade serous ovarian cancer and reports commercial updates, product revenue, and medical-conference data for the avutometinib and defactinib combination.
Recurring VSTM news also covers the company’s small-molecule pipeline, including RAF/MEK inhibition, FAK inhibition, and VS-7375, an oral KRAS G12D inhibitor studied in KRAS G12D-mutant solid tumors. Company updates commonly include clinical-trial analyses from RAMP studies, preclinical research presentations, FDA-related treatment context, patient advocacy resources for LGSOC, executive and employee equity grants, and quarterly financial results.
Verastem Oncology (Nasdaq: VSTM) reported Q1 2026 results and program updates on May 7, 2026. Net product revenue was $18.7M. Cash, cash equivalents and investments totaled $181.7M with an expected runway into the first half of 2027. The company initiated three Phase 2 TARGET-D trials for VS-7375 and expects TARGET-D 101 early data in 1H 2026 and mature data in 2H 2026.
RAMP 201J in Japan showed a confirmed ORR of 38% (57% in KRAS-mutant patients). Operating expenses and R&D increased in Q1.
Verastem Oncology (Nasdaq: VSTM) launched the Reimagine Recurrent LGSOC campaign to raise HCP and patient awareness of AVMAPKI FAKZYNJA CO-PACK (avutometinib; defactinib). The campaign highlights the FDA accelerated approval as the first and only therapy for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who received prior systemic therapy, and offers HCP and patient resources, educational tools, and dedicated websites.
Verastem Oncology (Nasdaq: VSTM) will report first quarter 2026 financial results and host a conference call and webcast on Thursday, May 7, 2026 at 4:30 PM ET.
A live audio webcast with accompanying slides will be available under Events & Presentations on the company investor website, with a replay archived after the event.
Verastem Oncology (NASDAQ: VSTM) reported two-year median follow-up data from the Phase 2 RAMP 201 trial of avutometinib plus defactinib in recurrent low-grade serous ovarian cancer (LGSOC).
With a median follow-up of 24.9 months, key efficacy measures remained consistent with the primary analysis: mDoR was 31.1 months in KRAS-mutant patients, mPFS reached 19.6 months in KRAS-mutant patients, and a 12% discontinuation rate due to adverse events was observed. Fifty percent of KRAS-mutated and 30% of KRAS wild-type patients stayed on therapy for over one year. No new safety signals were reported.
Verastem Oncology (Nasdaq: VSTM) granted 141,000 restricted stock units to eleven new employees as inducement awards under Nasdaq Listing Rule 5635(c)(4) on April 2, 2026. The RSUs vest 25% on the one-year hire anniversary, with the remainder vesting quarterly over the following three years, subject to continued service.
Verastem Oncology (Nasdaq: VSTM) announced multiple abstracts accepted for presentation at the AACR Annual Meeting, April 17-22, 2026, including late-breaking data released April 17. Preclinical results show the oral KRAS G12D dual ON/OFF inhibitor VS-7375 produced deeper, sustained tumor regressions versus ON-only RAS inhibitors across pancreatic, lung, and colorectal models.
In KP4 pancreatic xenografts, VS-7375 maintained mean tumor volume ~80 mm by day 30 versus >850 mm for comparator ON-only inhibitors, and VS-7375 showed strong activity combined with PRMT5 inhibition in MTAP-deleted models.
Verastem Oncology (Nasdaq: VSTM) will present long-term Phase 2 RAMP 201 data on the AVMAPKI FAKZYNJA combination (avutometinib capsules; defactinib tablets) at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers, April 10-13, 2026 in San Juan, Puerto Rico.
The plenary oral presentation on April 10 includes an additional year of follow-up versus the initial report and discusses long-term safety and efficacy in recurrent low-grade serous ovarian cancer patients with and without KRAS mutations. Verastem will also present posters and host an exhibit booth (#608).
Verastem Oncology (Nasdaq: VSTM) reported Q4 2025 net product revenues of $17.5M and full-year 2025 revenues of $30.9M following accelerated FDA approval of AVMAPKI FAKZYNJA CO-PACK in May 2025. The company reported cash, cash equivalents, and investments of $205M (pro forma $234.4M) and expects runway into H1 2027. VS-7375, an oral KRAS G12D inhibitor, cleared multiple dose levels with no DLTs and will progress toward Phase 2 registration-directed trials in PDAC, NSCLC and CRC combination plans.
R&D and SG&A rose materially; key milestones include RAMP 301 topline mid-2027 and VS-7375 early data in 1H 2026.
Verastem Oncology (Nasdaq: VSTM) will report its fourth quarter and full year 2025 financial results on Wednesday, March 4, 2026 at 4:30 PM ET. The company will host a conference call and live webcast covering results and business updates.
Investors can join by phone with passcode 7321921 or access a live audio webcast and slides via the Company's Investor Events page; a replay will be archived after the event.
Verastem Oncology (NASDAQ: VSTM) reported preliminary, unaudited AVMAPKI FAKZYNJA CO-PACK net product revenues of approximately $17.5M for 4Q25 and $30.9M for full‑year 2025 following FDA approval in May 2025. The company reported unaudited cash, cash equivalents and investments of $205M as of Dec 31, 2025, and pro forma cash of $234M after $29.4M in warrant exercises, with runway into the first half of 2027. Clinical highlights include RAMP201J Japan ORR 38% (57% in KRAS‑mutated LGSOC), fully enrolled confirmatory RAMP301 Phase 3, VS‑7375 dose escalations cleared to 900 mg QD and planned 2026 development milestones.